GSK to Acquire 35Pharma Inc in $950 Mn Deal

Under the terms of the agreement, GSK will acquire 100% of the equity of 35Pharma Inc. for $950 million, payable in cash at closing.

Global pharma giant, GSK has entered an agreement to acquire 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialising in the development of novel protein-based therapeutics.

The acquisition includes HS235, a potential best-in-class investigational medicine currently in clinical development for cardiopulmonary diseases.

Under the terms of the agreement, GSK will acquire 100% of the equity of 35Pharma Inc. for $950 million, payable in cash at closing.

Further, the transaction is subject to customary conditions, including regulatory clearances under the Hart-Scott-Rodino Act in the United States and the Competition Act in Canada, along with a filing under the Investment Canada Act.

Ilia Tikhomirov, CEO, 35Pharma, said, “In recent years, we witnessed a revolution in our understanding of pulmonary hypertension and how this life-threatening disease could be reversed. We are pleased to be joining forces with GSK, a leader in respiratory and inflammatory drivers of disease, who shares our vision of HS235’s potential to transform the treatment of this debilitating condition.”

35Pharma is developing therapeutics within the TGF-beta superfamily, with HS235 as its lead candidate for cardiopulmonary diseases.

GSK stated that the addition of HS235 strengthens its emerging pipeline of products with protective benefits on metabolic and vascular function within its Respiratory, Immunology and Inflammation portfolio.

Sharing thoughts, Tony Wood, Chief Scientific Officer, GSK, said, “Pulmonary hypertension affects millions of people worldwide, yet patients are underserved. We’re delighted to add HS235 to our pipeline, a potential best-in-class medicine with a differentiated profile to reduce risk of bleeding and provide potential metabolic benefits clinically relevant to PH patients. HS235’s potential protective effects on vascular function, alongside potential benefits on fat-derived markers of metabolism and inflammation, also offer new development opportunities within our RI&I portfolio to achieve broader coverage across the metabolic, inflammatory, vascular and fibrotic drivers of multiple chronic diseases that affect the lung, liver and kidney.”

Stay tuned for more such updates on Digital Health News